{'fraction_non_alphanumeric': 0.034255599472990776, 'fraction_numerical': 0.022397891963109356, 'mean_word_length': 4.9375, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dihydropyrimidine Dehydrogenase Activity in Human Pancreatic Tumor Tissues

Abstract Dihydropyrimidine dehydrogenase (DPD) activity was investigated using pancreatic tumors and normal pancreatic tissues surrounding the tumors obtained from. 12 patients with pancreatic cancer. The mean DPD activity (± SD) was 2.69 ± 1.88 nmol/mg protein/hr in normal pancreatic tissue and was 6.59 ± 5.36 nmol/mg protein/hr in pancreatic tumor tissues. The DPD activity in tumor tissue was two- to threefold higher (p < 0.07) than that in normal tissue, but no marked difference was observed in DPD activity among cancer stages. The DPD activity of pancreatic tumors may be a useful clinical marker of the responsibility of fluorinated pyrimidine dosing in pancreatic cancer.